GlycoMimetics Inc reports results for the quarter ended in June - Earnings Summary

Crescent Biopharma

02/08/2023 14:33

* GlycoMimetics Inc  GLYC.OQ  reported a quarterly adjusted
loss
of 13 cents​​ per share for the quarter ended in June. The mean
expectation of three analysts for the quarter was for a loss
of 18 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GlycoMimetics Inc's reported EPS for the quarter was a
loss
of 13 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * GlycoMimetics Inc shares had fallen by 5.2% this
quarter and
lost 45.5% so far this year.
    * The company reported a quarterly loss of $8.26 million.
    * Wall Street's median 12-month price target for
GlycoMimetics Inc
is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 2 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.18          -0.13          Beat
 Mar. 31 2023      -0.17          -0.17          Met
 Dec. 31 2022      -0.17          -0.19          Missed
 Sep. 30 2022      -0.26          -0.16          Beat